Document is current
Any future updates will be listed below
-
Authors
Estrada, Juan
Zhan, Jinghui
Mitchell, Petia
Werner, Jonathan
Beltran, Pedro J
DeVoss, Jason
Qing, Jing
Cooke, Keegan S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02263508 at ClinicalTrials.govnct02263508 at ClinicalTrials.govDocuments that mention this clinical trial
Commentary on oncolytic viruses: past, present, and future
https://doi.org/10.1136/jitc-2023-007905
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
https://doi.org/10.1136/jitc-2020-sitc2020.0429
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
https://doi.org/10.1136/jitc-2020-001621
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
https://doi.org/10.1200/jco.22.00343
OncoVEX<sup>mGM-CSF</sup>expands tumor antigen-specific CD8+ T-cell response in preclinical models
https://doi.org/10.1136/jitc-2022-006374
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
https://doi.org/10.1136/jitc-2024-009443
Efficacy of immune checkpoint inhibitors for in-transit melanoma
https://doi.org/10.1136/jitc-2019-000440
Documents that mention this clinical trial
Commentary on oncolytic viruses: past, present, and future
https://doi.org/10.1136/jitc-2023-007905
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma
https://doi.org/10.1136/jitc-2020-sitc2020.0429
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
https://doi.org/10.1136/jitc-2020-001621
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
https://doi.org/10.1200/jco.22.00343
OncoVEX<sup>mGM-CSF</sup>expands tumor antigen-specific CD8+ T-cell response in preclinical models
https://doi.org/10.1136/jitc-2022-006374
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
https://doi.org/10.1136/jitc-2024-009443
Efficacy of immune checkpoint inhibitors for in-transit melanoma
https://doi.org/10.1136/jitc-2019-000440
- License Information
